RxDoctor Payments Data

Richard Caputo, MD

Nephrology · St Augustine, FLNPI 1528062007

Payments from drug & device makers

$4,116in general payments, 2019–2025

Across 204 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$765
  • Novo Nordisk$638
  • Amgen$406
  • Esperion Therapeutics, Inc.$376
  • Otsuka America Pharmaceutical, Inc.$358
  • Novartis$355
  • plus $1K from 14 others

What the payments were for

  • Speaking & faculty fees$1504%
  • Food & beverage$3,75791%
  • Education$2095%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,116 in reported general payments places this provider in the 65th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$117,008
Medicare patients
159
Services billed
867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab533$401,060
OzempicSemaglutide131$190,541
Praluent PenAlirocumab87$65,121
EliquisApixaban59$60,092
MounjaroTirzepatide30$32,954
NexletolBempedoic Acid40$24,745
NexlizetBempedoic Acid/Ezetimibe56$24,632
BrilintaTicagrelor13$13,715
EntrestoSacubitril/Valsartan11$13,288
JanuviaSitagliptin Phosphate13$10,916
LivaloPitavastatin Calcium22$8,207
Candesartan Cilexetil75$5,030
Febuxostat38$3,985
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen131$3,938
Celecoxib146$3,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$638$190,541131 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$376$49,37696 claims
AstraZenecaBrilinta$765$13,71513 claims
NovartisEntresto$355$13,28811 claims
Kowa Pharmaceuticals America, Inc.Livalo$110$8,20722 claims
Sanofi-aventis U.S. LLCLantus$120$83812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 756 nephrology providers in Florida.

Other nephrology in St Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →